Research
Online Inquiry

Nocodazole Cell Cycle Synchronization Reagent

Cat.No: CCAT-HMM-0054 Datasheet

Quantities:
- +
Product Details Related Products
Product Name Nocodazole Cell Cycle Synchronization Reagent
Catalog No. CCAT-HMM-0054
Description A high-purity cell-permeable microtubule polymerization inhibitor that arrests cells at the G2/M phase boundary by disrupting mitotic spindle formation. Nocodazole synchronizes cycling cells at prometaphase by interfering with microtubule dynamics and activating the spindle assembly checkpoint.
Intended Use Cell cycle synchronization for biochemical analysis of cell cycle-regulated proteins, preparation of mitotic cell populations for chromosome analysis, and study of mitotic checkpoint signaling mechanisms.
Principle / Technology Nocodazole (methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate) binds to β-tubulin with high affinity and prevents the assembly of tubulin dimers into microtubules; inhibition of spindle microtubule polymerization activates the spindle assembly checkpoint (SAC), blocking the anaphase-promoting complex/cyclosome (APC/C) and arresting cells at the G2/M transition; the effect is reversible upon compound washout, allowing synchronized release into subsequent cell cycle phases.
Detection Method Flow cytometric DNA content analysis (propidium iodide staining) to verify G2/M accumulation; phospho-histone H3 (Ser10) immunostaining for mitotic index; time-lapse microscopy for mitotic progression monitoring
Sample Type Proliferating adherent and suspension mammalian cell lines; typically HeLa, U2OS, HEK293, CHO, and other rapidly dividing cell types
Performance Range / Specifications Optimal working concentration: 40–100 ng/mL (0.13–0.33 μM) depending on cell type; treatment duration: 12–18 hours for complete G2/M arrest; typical mitotic index yield: 70–95% of cell population; reversible release within 30–60 minutes of washout
Sensitivity / LOD Achieves >80% G2/M arrest in HeLa cells at 50 ng/mL with 16-hour treatment; synchronized release yields >60% cells progressing synchronously through G1 phase within 2 hours
Specificity Nocodazole specifically binds β-tubulin with a Kd of approximately 0.2 μM; minimal binding to actin or intermediate filaments; does not interfere with nucleic acid synthesis; microtubule depolymerization is microtubule-specific and calcium-independent
Reaction Conditions / Protocol Prepare 10 mg/mL nocodazole stock in DMSO; add to culture medium at recommended concentration (typically 50 ng/mL final with ≤0.1% DMSO); incubate cells for 12–18 hours at 37°C with 5% CO2; mitotic cells can be harvested by gentle shake-off due to rounded morphology and weakened attachment; to release, wash cells twice with warm PBS and add fresh medium; harvest at desired time points for cell cycle analysis
Components / Formulation Nocodazole (≥99% purity by HPLC) supplied as lyophilized powder; molecular weight 301.3 g/mol; soluble in DMSO at ≥20 mg/mL; recommended to prepare 10 mg/mL stock in anhydrous DMSO and store in single-use aliquots
Storage Conditions Lyophilized powder: -20°C protected from light and moisture, stable 36 months; DMSO stock (10 mg/mL): -20°C protected from light and moisture, stable 6 months
Shelf Life 36 months from date of manufacture for lyophilized powder
Package Specifications 10 mg, 25 mg, 50 mg, 100 mg lyophilized powder
Product Form Lyophilized powder requiring dissolution in DMSO
Quality Control Each lot analyzed by HPLC for purity (≥99% specification); biological activity confirmed in HeLa cell cycle arrest assay with >80% G2/M accumulation at 50 ng/mL; residual solvent tested; heavy metals within ICH Q3D limits
Key Features Most widely used G2/M synchronizing agent in cell cycle research; rapid and fully reversible activity; effective across a broad range of mammalian species and cell types; compatible with subsequent proteomic, genomic, and biochemical analyses; mitotic shake-off enables enrichment without trypsinization

For research use only, not for clinical use.

0
0

There is no product in your cart.